Shattuck Labs Executives Stick to Rule‑Based Trading: No Big Accumulations Despite Rally.
Shattuck Labs CTO’s disciplined 23k-share Rule 10(b)(5)(1) buys & sells reveal rule‑based equity management, not speculative bets.
3 minutes to read
SHATTUCK LABS INC
Siegall Clay B Buys 62,500 Shares at Offering Price, Signaling Confidence in Shattuck Labs’ $75 Million Capital Raise
Insider Siegall Clay B buys 62,500 shares of Shattuck Labs at the upcoming offering price, signaling confidence in the $75 M financing and Phase 2b plans for SL‑325.
3 minutes to read
OrbiMed’s $15 M Pre‑Funded Warrant Buy at Shattuck Labs Signals Bullish Confidence Ahead of SL‑325 Phase 1 Data
OrbiMed’s $15 M pre‑funded warrant buy at Shattuck Labs signals strong confidence ahead of Phase 1 data, hinting at potential upside and strategic board influence.
4 minutes to read
CEO Schreiber Taylor Buys 25,610 Shares at $1.08, Boosting Confidence Amid Shattuck Labs’ Clinical Expansion Plans
CEO Schreiber Taylor’s May 12, 2026 share buy‑back at $1.08 signals strong insider confidence in Shattuck Labs’ undervalued stock and upcoming Phase‑2 clinical data, urging investors to monitor the potential rally amid high volatility.
3 minutes to read